How does Viking's drug compete with Eli Lilly and Novo Nordisk?

It features a different mechanism that may offer greater weight loss efficacy, but it is still in early stages.

Viking Therapeutics Begins Trial for Weight Loss Drug Beyond GLP-1

Q: When will Viking's obesity drug be available?

Not yet announced; clinical trials are expected to take several years before approval.

Viking Therapeutics has initiated a clinical trial for a novel obesity drug that targets pathways beyond GLP-1, positioning it against Eli Lilly and Novo Nordisk. The drug aims for greater weight loss efficacy.

July 18, 2026

2 min read

Source: Motley Fool

Viking Therapeutics (ticker: VKTX) announced the start of a clinical trial for a new obesity drug that works via mechanisms beyond GLP-1 receptors. This comes amid fierce competition in the weight loss drug market between Eli Lilly (LLY) and Novo Nordisk.

The Product

The new drug, whose name has not been disclosed, targets novel biological pathways beyond GLP-1 to achieve greater weight loss with fewer side effects. According to the company, the drug showed promising results in animal models.

Pricing and Availability

The company has not yet disclosed pricing details or a timeline for the trials. Clinical trials are expected to take several years before potential FDA approval.

Competition

Viking faces strong competition from drugs like Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Mounjaro and Zepbound. However, the new drug's different mechanism of action could provide a competitive edge if proven effective.

Potential Impact on the Company

If successful, the trials could position Viking strongly in the growing obesity market, valued at tens of billions of dollars. However, risks are high as most drugs fail in clinical trials.

Frequently Asked Questions

A new obesity drug that works via mechanisms beyond GLP-1 receptors; its name has not been disclosed.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.